For generations, cancer has hidden in the body's silence until it speaks too loudly to answer. A landmark clinical trial now suggests that a single blood draw, read by machine-learning algorithms trained to recognize the molecular signatures of malignancy, may begin to change that equation — detecting more than fifty cancer types earlier, when the possibility of cure still exists. The PATHFINDER 2 study, enrolling nearly 36,000 adults across North America, found that adding the Galleri multi-cancer test to standard screening increased cancer detection 6.5-fold, with the majority of newly found
Blood test for 50+ cancers boosts early detection 6.5-fold in major trial
Early detection enabled curative treatment for patients with previously undetectable cancers like bile duct cancer and hepatocellular carcinoma.
Early detection didn't just find the cancer—it preserved his options for a cure.
Mark
So this test found 6.5 times more cancers. That's a striking number. But I want to understand what that actually means—are we talking about finding the same cancers earlier, or finding cancers that would have been missed entirely?
Mimi
Both, really. The test found cancers that standard screening would never have caught—seventy percent of the newly detected cancers were types without routine screening recommendations. But it also found cancers earlier, when they're still localized and treatable.
Luke
Wait—6.5 times more cancers detected. But how many of those would have shown up anyway in the next year or two? The trial wasn't randomized, so we don't actually know if this shifts the overall stage distribution in a population.
Mimi
That's fair. The UK trial was randomized, and it didn't show a statistically significant reduction in combined stage three and four cancers. But it did show stage four diagnoses fell by more than twenty percent in later screening rounds.
Mark
So the UK trial is the real test of whether this actually saves lives?
Mimi
It's one piece. PATHFINDER 2 shows the test works—it finds cancers, it's accurate, it's safe. The UK trial is exploring whether finding those cancers earlier actually changes outcomes. They're different questions.
Luke
And the positive predictive value is 60 percent. That means four in ten positive results don't lead to a cancer diagnosis. Is that good?
Mimi
For a screening test, especially one looking for fifty-plus cancers, that's actually quite strong. Most traditional screening tests have lower predictive values. And the false-positive rate is 0.36 percent—extraordinarily low.
Mark
What about the patients in the trial? Did any of them actually benefit in a way we can measure?
Mimi
Franklin Weingarten had a bile duct cancer caught early enough to be surgically removed. He's eighty-eight now and cancer-free. Bart Dawkins had early-stage liver cancer caught at a stage where transplant is possible. Those are real outcomes.
Luke
But those are anecdotes from a trial where everyone got the test. We don't know how many people got unnecessary workups, or how many got false reassurance from a negative result.
Mimi
True. But the trial did track safety—only 0.6 percent of participants had an invasive procedure after a positive result. Most weren't surgical.
Mark
What happens next?
Mimi
The FDA is reviewing it for approval. OHSU is running follow-up studies—one in Medicare beneficiaries, another in people with genetic cancer risk. The real question is whether this becomes standard screening or stays specialized.
Luke
And whether insurance will pay for it, and whether it actually reduces cancer deaths at a population level. Those are still open questions.
The Pulse
- Dozens of cancers — pancreatic, ovarian, bile duct, liver — currently have no routine screening, meaning they are typically found only after symptoms emerge and the window for cure has often closed.
- The PATHFINDER 2 trial's scale — 35,878 participants, 6.5-fold increase in detection — creates urgent pressure on regulators and health systems to decide how quickly this test can move from research into routine care.
- A false-positive rate of just 0.36 percent and a 91 percent accuracy in predicting cancer location give clinicians a navigational tool that minimizes unnecessary procedures while directing diagnostic effort precisely.
- Individual patients — an 84-year-old physician whose bile duct cancer was removed before symptoms appeared, a 68-year-old now eligible for liver transplantation — embody what earlier detection means in human terms.
- A parallel UK trial of nearly 140,000 participants shows stage 4 diagnoses falling by more than 20 percent in later screening rounds, suggesting the test's full benefit may only become visible across multiple years of use.
- The FDA advisory review, expanding Medicare trials, and planned studies targeting high-risk populations mark the path from landmark result to standard of care — a journey still underway but now moving with evidence behind it.
For generations, cancer has hidden in the body's silence until it speaks too loudly to answer. A landmark clinical trial now suggests that a single blood draw, read by machine-learning algorithms trained to recognize the molecular signatures of malignancy, may begin to change that equation — detecting more than fifty cancer types earlier, when the possibility of cure still exists. The PATHFINDER 2 study, enrolling nearly 36,000 adults across North America, found that adding the Galleri multi-cancer test to standard screening increased cancer detection 6.5-fold, with the majority of newly found cancers caught at stages when treatment can still be curative. As the FDA prepares to weigh the evidence, medicine stands at one of those rare thresholds where a technological possibility begins to harden into clinical reality.
A blood test capable of screening for more than fifty cancers has dramatically improved early detection when added to standard screening protocols, according to results from the PATHFINDER 2 trial published this week in Nature Medicine. Enrolling 35,878 adults aged fifty and older across the United States and Canada, the study found that the Galleri test — which uses machine-learning to identify cancer-associated patterns in cell-free DNA — increased overall cancer detection by 6.5 times compared to conventional screening alone.
The findings address a critical gap: Americans are routinely screened for only five cancers, which account for roughly thirty percent of cancer deaths. Cancers of the pancreas, ovaries, liver, and bile duct typically go undetected until symptoms appear and the disease is advanced. In PATHFINDER 2, seventy percent of the cancers newly identified by the blood test were types with no national screening recommendation, and nearly half were caught at stages one or two — the window when curative treatment remains possible. The test returned a false-positive rate of just 0.36 percent and correctly predicted the cancer's location in the body more than ninety-one percent of the time.
The human stakes were made vivid by two Oregon patients. Franklin Weingarten, an eighty-four-year-old retired physician, received a positive signal that led to an early diagnosis of cholangiocarcinoma — a bile duct cancer almost never found before symptoms develop. Surgeons removed part of his liver, and at eighty-eight he remains cancer-free. Bart Dawkins, sixty-eight, was similarly guided to an early-stage liver cancer diagnosis and is now being evaluated for transplantation, an option that would have been foreclosed by a later discovery.
Oregon Health & Science University's Knight Cancer Institute served as the trial's largest enrollment site, contributing roughly 6,100 participants through partnerships spanning rural Oregon communities, and has emerged as a national leader in multi-cancer early detection research. Complementary results from the UK's NHS-Galleri trial — nearly 140,000 participants — showed a greater than twenty percent drop in stage four diagnoses across twelve deadly cancers in later screening rounds, suggesting the test's benefit deepens with repeated use over time.
With an FDA advisory committee now reviewing the evidence, and new studies targeting Medicare beneficiaries and high-risk populations already underway, researchers describe this moment as a genuine watershed — one where the long-imagined possibility of catching cancer before it speaks is beginning, carefully and rigorously, to become medicine.
A single blood draw that screens for more than fifty different cancers has substantially improved early cancer detection when used alongside standard screening protocols, according to results from a major clinical trial published this week in Nature Medicine. The PATHFINDER 2 study, which enrolled 35,878 adults aged fifty and older across the United States and Canada, found that adding the Galleri blood test to conventional screening increased overall cancer detection by 6.5 times. The test uses machine-learning algorithms to identify chemical patterns in cell-free DNA that distinguish cancerous cells from healthy ones, and the results arrive as the Food and Drug Administration's advisory committee prepares to review evidence for the test's potential approval.
The trial's scale and findings address a fundamental gap in current cancer screening practice. Americans are routinely screened for five cancers—breast, colorectal, cervical, lung, and prostate—yet these account for only about thirty percent of cancer deaths. Pancreatic, ovarian, liver, and bile duct cancers, among others, typically go undetected until symptoms appear, by which point the disease is often advanced and far more difficult to treat. In PATHFINDER 2, seventy percent of the cancers newly identified by the blood test were types that currently lack national screening recommendations. Among those newly detected cancers, nearly half were diagnosed at stages one or two, and nearly three-quarters at stages one through three—the window when curative treatment remains possible.
The test demonstrated a positive predictive value of 60.3 percent, meaning that when it returned a positive result, there was at least a sixty percent chance that cancer would ultimately be found. It also showed a specificity of 99.64 percent, translating to a false-positive rate of just 0.36 percent. Nima Nabavizadeh, the lead author and a professor of radiation medicine at Oregon Health & Science University's Knight Cancer Institute, emphasized that this low false-positive rate represents a significant advantage over many traditional screening tests. The test also correctly predicted the cancer's location in the body 91.3 percent of the time, allowing clinicians to focus diagnostic efforts efficiently. Among the more than 35,000 participants evaluated for safety, only 0.6 percent underwent an invasive procedure following a positive result, and most of those were nonsurgical.
The human impact of early detection emerged through individual patient stories. Franklin Weingarten, an eighty-four-year-old retired Oregon physician enrolled in the study, received a positive cancer signal that led to a diagnosis of cholangiocarcinoma, a rare bile duct cancer with no routine screening test and typically discovered only after symptoms develop. Because his cancer was found early and localized, surgeons were able to remove part of his liver. Now eighty-eight, Weingarten remains cancer-free and credits the test with extending his life by years. "If I had waited until I had any symptoms, the disease would have been essentially incurable," he said. Similarly, Bart Dawkins, sixty-eight, of The Dalles, Oregon, received a positive signal leading to diagnosis of early-stage hepatocellular carcinoma. The rapid diagnostic workup guided by the test's location prediction connected him quickly to OHSU's liver team for treatment, and he is now being evaluated for liver transplantation—an option that would not have existed had the cancer been discovered at a later stage.
Oregon Health & Science University's Knight Cancer Institute served as the largest enrollment site for PATHFINDER 2, bringing in approximately 6,100 participants through its Knight Early Detection Clinical Research team and partners across the state, including rural practice networks in the Columbia River Gorge, St. Charles Health System in Bend, Salem Hospital, and Bay Area Hospital in Coos Bay. The trial represents what may be the largest interventional clinical trial ever conducted through the institute and has positioned OHSU as a national leader in the emerging field of multi-cancer early detection. Nabavizadeh noted that the clinical research team now has arguably the most robust experience in the world managing these tests, interpreting results, and designing diagnostic pathways for patients with positive findings.
Complementary evidence comes from a separate randomized controlled trial in the United Kingdom, NHS-Galleri, which enrolled nearly 140,000 participants and published results today in the New England Journal of Medicine. While that trial did not find a statistically significant reduction in combined stage three and four cancers, a favorable trend emerged over time. Across twelve of the deadliest cancers, stage four diagnoses fell by more than twenty percent in the second and third screening rounds, while cancers caught at stages one and two increased markedly, and the overall detection rate was approximately four-fold higher when the blood test was added to standard screening. Nabavizadeh suggested that the combined stage three and four result likely reflects a feature of first-year population screening—a reservoir of previously undetected, asymptomatic stage three cancers that the test surfaces all at once.
Looking forward, OHSU is enrolling participants in the REACH study, which evaluates annual multi-cancer early detection testing among Medicare beneficiaries, with enrollment expanding to community sites across Oregon. The institute is also preparing to launch INFORM, a collaboration with Dana-Farber Cancer Institute, which will evaluate the test among people identified as having inherited cancer risk, strong family histories, or genetic cancer predisposition syndromes, with plans to provide at-home access through telehealth and mobile phlebotomy. As federal review continues, researchers emphasize that while the promise of detecting dozens of cancers through a single blood draw is real, rigorous clinical trials are how such technology earns its place in clinical practice. The field stands at what Nabavizadeh calls a watershed moment—one where the evidence is beginning to match the possibility.
Notable Quotes
If I had waited until I had any symptoms, the disease would have been essentially incurable. I have already been given a two-year life extension.— Franklin Weingarten, 88, retired physician diagnosed with bile duct cancer through the test
Catching Bart's cancer at the stage we did is what allowed him to be a candidate for curative therapy, up to and including a liver transplant.— Nima Nabavizadeh, lead researcher, on early detection enabling treatment options
Want the full story?
Read the original at News-Medical ↗
Health & Medicine